Ace the 2026 RAC Exam – Unleash Your Regulatory Expertise Today!

A company developing an autologous cellular therapy must adhere to all Subparts of 21 CFR 1271 because this regulation outlines the requirements for human cellular and tissue-based products (HCT/Ps). Subpart A establishes the general provisions that define the scope, definitions, and jurisdiction, while Subpart B focuses on the safety and effectiveness of these products.

In the context of autologous cellular therapies, which involve using a patient’s own cells for treatment, all sections of 21 CFR 1271 are relevant. This ensures that the product is manufactured, processed, packaged, and labeled in accordance with stringent safety standards, thereby supporting regulatory compliance during development, clinical use, and commercialization. Compliance with these comprehensive regulations is crucial to ensure patient safety and product efficacy, which are paramount in therapeutic applications.

The other choices do not encompass the complete regulatory framework necessary to address all aspects of compliance related to HCT/Ps, making option B the most comprehensive and thus the correct choice.